The NCCN Clinical Practice Guidelines in Oncology for non-small cell lung cancer (NSCLC), recommend the molecular testing of clinically proven predictive biomarkers, namely, ALK, BRAF, EGFR, KRAS, MET exon14 skipping, NTRK1/2/3, RET and ROS1 genes, and a few emerging ones such as MET amplification and ERBB2 mutations (Kristina Gregory et al., 2022). This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.